Bayesian Capital Management, LP Sage Therapeutics, Inc. Transaction History

Bayesian Capital Management, LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$17.1 - $22.26 $708,367 - $922,120	41,425 New	41,425 $897,000
Q3 2022 Nov 14, 2022	BUY	$32.28 - $43.27 $219,504 - $294,236	6,800 New	6,800 $266,000
Q4 2019 Feb 14, 2020	SELL	$60.18 - $154.77 $109,948 - $282,764	-1,827 Closed	0 $0
Q3 2019 Nov 13, 2019	BUY	$140.29 - $189.96 $256,309 - $347,056	1,827 New	1,827 $256,000
Q1 2019 May 14, 2019	SELL	$89.33 - $163.65 $204,565 - $374,758	-2,290 Closed	0 $0

Q4 2018 Feb 13, 2019	BUY	$81.94 - $139.71 $187,642 - $319,935	2,290 New	2,290 $219,000
Q4 2017 Feb 12, 2018	SELL	$60.72 - $167.34 $272,754 - $751,691	-4,492 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$61.4 - $88.52 $275,808 - $397,631	4,492	4,492 $280,000

222

52.7M

207K

191K

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $641M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

Get notified when there are updates to the investment portfolio of Bayesian Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Bayesian Capital Management, LP with notifications on news.